Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 May 2022 | Story Rulanzen Martin | Photo Supplied
Jon Kehrer
Jon Kehrer is a prolific academic and scholar. He also spent a few years teaching English in the Middle East.

It was a former professor who influenced American scholar Jon Kehrer to further his academic journey with the Department of Hebrew at the University of the Free State (UFS). And it was at the UFS where he recently graduated cum laude with a master’s degree in Hebrew, and was named recipient of the Dean’s Medal. 

Although he never expected to receive the Dean’s Medal, he is very glad – and somewhat relieved – that his dissertation made it through the examiners. “I never anticipated receiving this award. It makes me even more grateful for the strong Hebrew Department at UFS, and their rigorous standards for their students,” Kehrer says. 

“I wish I had been able to attend the graduation ceremony, but the circumstances of the semester just did not allow it.” Kehrer is currently teaching in the areas of the Old Testament and Biblical Languages at the Ozark Christian College (OCC) in Missouri, USA. In addition to his UFS qualifications Kehrer also holds a Bachelor of Theology qualification from the OCC. “I love the opportunity to invest in students and help them see new perspectives,” he says. 

UFS Hebrew a firm foundation for a solid academic career  

“I was looking for a high-quality and challenging programme that was flexible, especially since I work full-time and have a large family,” Kehrer says, as he recalls how he initially decided to become part of the UFS. He remembers fondly how Dr Kevin Chau, senior lecturer in Hebrew at the UFS, motivated and supported him when he first enrolled for the BA Honours programme. 

It is also a testament that the Department of Hebrew has made an impact internationally for the quality of its academic offerings. “Dr Chau helped me to think about how what I was learning would have an impact on my research and teaching in the future, and he was always quick to provide thorough and constructive feedback on my work,” Kehrer says.  

Once enrolled for the master’s programme it was initially difficult to know which direction to pursue and what topic to research, but the guidance and support of his two advisors, Prof Cynthia Miller-Naude and Prof Jacobus Naude, was “very helpful”.

“They never dictated what paths I should pursue, but they listened carefully and provided expert guidance to help me choose the path that would best suit my interests and the needs of the field,” he says. 

It was this support from the Department of Hebrew and its excellent reputation that came full circle when Kehrer was named Dean’s Medal recipient for achieving the highest marks of any student in a master’s qualification in the UFS Faculty of The Humanities. 

Dissertation a closer look at verbs in Biblical Hebrew 

His dissertation focused on Biblical Hebrew and how the object of a verb appears in various ways. “Sometimes an object appears by itself, but sometimes it can have a preposition or a two-consonant Biblical Hebrew particle along with it. Many Bible translations treat all these objects the same,” he says. “I wanted to try to understand why these variations occurred, so I looked at how different sentence elements might contribute to the variation. It was a fascinating study!” 
 
Kehrer believes it is important for university students to continue studying classical subjects like Hebrew. “I think we can all learn much from those who have gone before us, and so much wisdom and insight is connected to these ancient Biblical Hebrew texts, texts that would be inaccessible to us without translation,” he says. 

“I also think classical disciplines can help train students to think well and to read critically – essential skills for living in today’s ever-changing world.”  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept